Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
Patent 6117855 Issued on September 12, 2000. Estimated Expiration Date: 
December 19, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
December 19, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesQuinuclidine therapeutic agents Medical use for tachykinin antagonists Substituted morpholine derivatives and their use as therapeutic agents Treatment of migraine with morpholine tachykinin receptor antagonists Morpholine and thiomorpholine tachykinin receptor antagonists Spiroketal derivatives, compositions containing them and their use as therapeutic agents Patent #: 5728695 InventorsAssigneeApplicationNo. 994063 filed on 12/19/1997US Classes:514/90, Chalcogen in the six-membered hetero ring514/236.2, Three or more ring hetero atoms in the additional hetero ring514/278, Spiro ring system514/329Nitrogen attached directly to the piperidine ring by nonionic bondingExaminersPrimary: Jarvis, William R. A.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/675A61K 031/535 A61K 031/44 A61K 031/445 Foreign Application Priority Data1996-10-07 GBAbstractThe present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of CNS-penetrant NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.Other References
| |
